Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

06/14/2021 | 08:26am EDT

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.

These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901).

The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI), 0.53-0.86; p=0.0013].1 Median progression-free survival (PFS) was not reached after nearly five years and the PFS benefit observed with D-Rd was maintained, with a 47 percent reduction in risk of disease progression or death [HR: 0.53; 95 percent CI, 0.43-0.66; p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
11:03aJOHNSON & JOHNSON : Vaccine Tourism is Taking Off at SFO; Over 30,000 vaccines a..
AQ
08/04JOHNSON & JOHNSON : FDA - Coronavirus Update
AQ
08/04JOHNSON & JOHNSON : U.S. Govt Donates 151,200 Doses of J&J Vaccines to MoH
AQ
08/04JOHNSON & JOHNSON : 11,000 Tunisian Students Studying Abroad to Receive Covid-19..
AQ
08/03ZYMEWORKS : Says Earned Milestone Payment From Johnson & Johnson Under Licensing..
MT
08/03Johnson & Johnson Appoints Sandipan Ghatak as Head of Consumer Health India C..
CI
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
AQ
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
AQ
08/03JOHNSON & JOHNSON : Eyes Ways To Fast-Track COVID-19 Vaccine Delivery To India
MT
08/02JOHNSON & JOHNSON : Janssen Pharmaceutical - UPTRAVI Receives FDA Approval for I..
AQ
More news
Financials (USD)
Sales 2021 94 457 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,3x
Yield 2021 2,40%
Capitalization 456 B 456 B -
EV / Sales 2021 4,84x
EV / Sales 2022 4,62x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 173,36 $
Average target price 184,35 $
Spread / Average Target 6,34%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613
NOVO NORDISK A/S43.21%222 926